Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | AOC2 | O75106 | 4/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 6/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.34 |
| ▸ | CKS1B | P61024 | 1/20 | 0.33 |
| ▸ | SKP1 | P63208 | 1/20 | 0.33 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30527037 | 1.00 | L3MBTL1 (0.39) | L3MBTL1AOC2MAOBAOC3SCN9A | |
| SCHEMBL21042102 | 1.00 | L3MBTL1 (0.39) | L3MBTL1AOC2MAOBAOC3SCN9A | |
| SCHEMBL22462034 | 0.87 | AOC2 (0.36) | AOC2MAOBAOC3SCN9A | |
| SCHEMBL22462035 | 0.87 | AOC2 (0.36) | AOC2MAOBAOC3SCN9A | |
| SCHEMBL28666193 | 0.82 | AOC3 (0.41) | AOC2MAOBAOC3CA12CA1 | |
| SCHEMBL22462047 | 0.80 | AOC2 (0.49) | AOC2MAOBAOC3 | |
| SCHEMBL21040306 | 0.80 | AOC2 (0.49) | AOC2MAOBAOC3 | |
| SCHEMBL30527072 | 0.80 | AOC2 (0.49) | AOC2MAOBAOC3 | |
| SCHEMBL28666101 | 0.80 | AOC3 (0.39) | AOC2MAOBAOC3CA12CA1 | |
| SCHEMBL28668740 | 0.80 | AOC3 (0.39) | AOC2MAOBAOC3CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649233-B2 | Halo-allylamine SSAO/VAP-1 inhibitor and use thereof | NANJING TRANSTHERA BIOSCIENCES CO., LTD. (CN) | 2023-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649233-B2 | Halo-allylamine SSAO/VAP-1 inhibitor and use thereof | VAPB, VAPA, ADRA1D | L3MBTL1 1172/4885AOC2 102/4885MAOB 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.